EWTX vs. KURA, ZGNX, ARCT, XENT, ANAB, SMMT, OGN, IONS, BBIO, and CYTK
Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Kura Oncology (KURA), Zogenix (ZGNX), Arcturus Therapeutics (ARCT), Intersect ENT (XENT), AnaptysBio (ANAB), Summit Therapeutics (SMMT), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
Kura Oncology (NASDAQ:KURA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
Kura Oncology has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.
Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Kura Oncology's return on equity of -29.09% beat Edgewise Therapeutics' return on equity.
Kura Oncology received 383 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 69.01% of users gave Kura Oncology an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
In the previous week, Kura Oncology and Kura Oncology both had 3 articles in the media. Kura Oncology's average media sentiment score of 1.82 beat Edgewise Therapeutics' score of 0.86 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.
Kura Oncology presently has a consensus price target of $27.94, suggesting a potential upside of 35.55%. Edgewise Therapeutics has a consensus price target of $31.20, suggesting a potential upside of 82.14%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Kura Oncology.
Summary
Edgewise Therapeutics beats Kura Oncology on 7 of the 12 factors compared between the two stocks.
Get Edgewise Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edgewise Therapeutics Competitors List
Related Companies and Tools
